Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib

J Natl Cancer Inst. 2015 Nov 12;108(1):djv307. doi: 10.1093/jnci/djv307. Print 2016 Jan.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Crizotinib
  • Fibrosarcoma / congenital
  • Fibrosarcoma / drug therapy*
  • Fibrosarcoma / genetics*
  • Fibrosarcoma / pathology
  • Fibrosarcoma / surgery
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Gene Fusion*
  • Humans
  • Infant
  • Lamin Type A / genetics*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / secondary
  • Molecular Targeted Therapy
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrazoles / administration & dosage
  • Pyrazoles / pharmacology*
  • Pyridines / administration & dosage
  • Pyridines / pharmacology*
  • Receptor, trkA / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Spinal Neoplasms / drug therapy
  • Spinal Neoplasms / secondary
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • LMNA protein, human
  • Lamin Type A
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • Receptor, trkA